沙库巴曲缬沙坦用于失代偿性心力衰竭住院患者:PIONEER-HF与PARAGLIDE-HF汇总分析
该汇总分析纳入PIONEER-HF和PARAGLIDE-HF两项双盲随机试验共1347例近期心衰恶化后稳定的患者,比较沙库巴曲缬沙坦与对照治疗(依那普利或缬沙坦)。结果显示沙库巴曲缬沙坦使NT-proBNP降低幅度增加24%,心血管死亡或心衰住院风险降低30%,且效应在EF≤60%范围内一致。
要点
- 沙库巴曲缬沙坦较对照使NT-proBNP降低幅度增加24%(ratio of change=0.76)。
- 心血管死亡或心衰住院风险降低30%(HR 0.70)。
- 效应在EF≤60%范围内一致,但症状性低血压风险增加(RR 1.35)。
核心结论
- 在心衰恶化后稳定的患者中,沙库巴曲缬沙坦较对照治疗更显著降低血浆NT-proBNP并改善临床结局,尤其在EF≤60%范围内。
研究设计与样本
- 汇总PIONEER-HF和PARAGLIDE-HF两项双盲随机试验,共1347例患者(PIONEER-HF 881例,PARAGLIDE-HF 466例)。
- PIONEER-HF全部患者及PARAGLIDE-HF 69.5%的患者在因心衰住院稳定后入组,PARAGLIDE-HF其余患者在心衰恶化事件后≤30天入组。
- 两项试验主要终点均为基线至第4周和第8周NT-proBNP的时间平均比例变化。
主要发现
- 基线中位年龄66岁,女性36%,黑人31%,新发心衰34%,中位EF 30%。
- 沙库巴曲缬沙坦较对照使NT-proBNP降低幅度增加24%(n=1130;ratio of change=0.76;95%CI:0.69-0.83;P<0.0001)。
- 心血管死亡或心衰住院风险降低30%(HR:0.70;95%CI:0.54-0.91;P=0.0077),效应在EF≤60%范围内一致。
- 沙库巴曲缬沙坦增加症状性低血压风险(risk ratio:1.35;95%CI:1.05-1.72)。
关键数值与推荐
- 主要终点为NT-proBNP从基线至第4周和第8周的时间平均比例变化。
- 临床终点经裁定并调整试验因素后分析至随访结束。
临床怎么用
- 对于心衰恶化后稳定的住院患者,可考虑使用沙库巴曲缬沙坦以降低NT-proBNP并改善临床结局。
- 在EF≤60%范围内均可观察到一致的临床获益。
- 使用时需注意监测症状性低血压风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been described. OBJECTIVES: Data from randomized trials of sacubitril/valsartan in HF patients with EF ≤40% (PIONEER-HF [Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF] trial) following recent worsening heart failure (WHF) were pooled to examine treatment effect across the EF spectrum. METHODS: The PIONEER-HF and PARAGLIDE-HF trials were double-blind, randomized trials of sacubitril/valsartan vs control therapy (enalapril or valsartan, respectively). All participants in the PIONEER-HF trial and 69.5% in the PARAGLIDE-HF trial were enrolled during hospitalization for HF after stabilization. The remainder in the PARAGLIDE-HF trial were enrolled ≤30 days after a WHF event. The primary endpoint of both trials was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8. Adjudicated clinical endpoints were analyzed through the end of follow-up, adjusting for trial. RESULTS: The pooled analysis included 1,347 patients (881 from PIONEER-HF, 466 from PARAGLIDE-HF). Baseline characteristics included median age 66 years, 36% women, 31% Black, 34% de novo HF, and median EF 30%. The reduction in NT-proBNP was 24% greater with sacubitril/valsartan vs control therapy (n = 1,130; ratio of change = 0.76; 95% CI: 0.69-0.83; P < 0.0001). Cardiovascular death or hospitalization for HF was reduced by 30% with sacubitril/valsartan vs control therapy (HR: 0.70; 95% CI: 0.54-0.91; P = 0.0077). This effect was consistent across the spectrum of EF ≤60%. Sacubitril/valsartan increased symptomatic hypotension (risk ratio: 1.35; 95% CI: 1.05-1.72). CONCLUSIONS: In patients stabilized after WHF, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP and improved clinical outcome compared with control therapy, in particular across the spectrum of EF ≤60%. (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event [HFpEF Decompensation] Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation [PARAGLIDE-HF]; NCT03988634).
引用
- Morrow, Velazquez, Desai, et al. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. J Am Coll Cardiol. 2024. PMID: 38508844. doi:10.1016/j.jacc.2024.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。